Mani Subramanian, MD, PhD

Dr. Mani Subramanian is the CEO of the Liver Company. In 2020, he joined Samsara as a Venture Partner, responsible for evaluating investment opportunities and incubating innovative R&D efforts within Samsara, focused on developing transformational therapies for the treatment of patients with liver diseases.

Subramanian was previously at Gilead Sciences from 2011-2020, where he was the Senior Vice President and Therapeutic Area Head for Liver Diseases. He was responsible for the developing and implementing the R&D vision for liver diseases, which lead to the approval of compounds for the treatment of patients with viral hepatitis (Sovaldi, Harvoni, Epclusa, Vosevi, Vemlidy), and a compound portfolio in non-alcoholic steatohepatitis, cholestatic liver disease and alcoholic hepatitis.

From 2002-2010, he was at Human Genome Sciences, where he led programs in albumin-fusion proteins and monoclonal antibodies for immunology and infectious disease indications, notably clinical development of Zalbin for HCV, and Abthrax for anthrax. He started his biotechnology career at Celera Genomics in 2000 and was a major contributor to the proteome annotation of the human, mouse and anopheles genome sequencing efforts.

Subramanian received his medical degree at the Armed Forces Medical College, India, completed his PhD in Immunology & Microbiology at the University at Michigan-Ann Arbor, followed by residency in Internal Medicine at University Hospitals of Cleveland, Case Western Reserve University, and fellowship in Infectious Diseases, with post-doctoral research at the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH).